Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - tecovirimat
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp13b9c5485a5dae25afc0e0c660688026
identifier: http://ema.europa.eu/identifier
/EU/1/21/1600/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tecovirimat SIGA 200 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-13b9c5485a5dae25afc0e0c660688026
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1600/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tecovirimat
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Tecovirimat SIGA contains the active ingredient tecovirimat.
Tecovirimat SIGA is used to treat viral infections, such as smallpox, mpox and cowpox in adults and children weighing at least 13 kg.
Tecovirimat SIGA is also used to treat complications from smallpox vaccines.
Tecovirimat SIGA works by stopping the virus from spreading. This will help your own body to build up protection against the virus until you are better.
Do not take Tecovirimat SIGA
Warnings and precautions
Talk to your doctor or pharmacist before taking Tecovirimat SIGA.
Children weighing less than 13 kg
This medicine should not be given to children who weigh less than 13 kg.
Other medicines and Tecovirimat SIGA
Tell your doctor if you are taking, have recently taken or might take any other medicines.
You must tell your doctor if you are taking any of the following medicines:
Taking Tecovirimat SIGA with any of these may stop your medicines from working properly, or make any side effects worse. Your doctor may need to give you a different medicine or adjust the dose of medicine you are taking. The above is not a complete list of medicines that your doctor may need to alter.
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Tecovirimat SIGA is not recommended during pregnancy.
It is not known whether Tecovirmat SIGA is excreted in human milk. Breast-feeding is not recommended during treatment with this medicine. Tell your doctor if you are breast-feeding or are planning to breast-feed before taking this medicine.
Driving and using machines
Do not drive or operate machines if you feel dizzy.
Tecovirimat SIGA contains Lactose and sunset yellow (E110)
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Adults and children weighing at least 13 kg
The recommended doses are described in the table below.
Body Weight Dose 13 kg to less than 25 kg One Tecovirimat SIGA 200 mg capsule every 12 hours for 14 days (200 mg two times a day) 25 kg to less than 40 kg Two Tecovirimat SIGA 200 mg capsules every 12 hours for 14 days (400 mg two times a day) 40 kg to less than 120 kg Three Tecovirimat SIGA 200 mg capsules every 12 hours for 14 days (600 mg two times a day) 120 kg and above Three Tecovirimat SIGA 200 mg capsules every 8 hours for 14 days (600 mg three times a day)
Method of administration
Tecovirimat SIGA should be taken within 30 minutes of eating a meal of moderate calories and fat content.
Adults and children who have difficulty swallowing capsules
For patients who are not able to swallow the capsules, the doctor may recommend opening the hard capsule and mixing the contents with 30 mL of liquid (e.g., milk, chocolate milk) or soft food (e.g., apple sauce, yogurt).
Wash and dry your hands before and after preparation. Carefully open the capsule so that the contents do not spill or escape into the air. Hold the capsule with the cap facing up and pull the cap away from the body of the capsule. Use a small container for mixing. Mix the entire contents of the capsule with 30 mL of liquid (e.g. milk) or soft food (e.g. yogurt). The mixture should be taken within 30 minutes after mixing and within 30 minutes of eating a meal.
The recommended paediatric and adult dosage and preparation instructions are given in the table below.
Body weight Tecovirimat dose Amount of liquid or soft food Number of capsules Food and tecovirimat mixture instructions 13 kg to less than 25 kg 200 mg 2 tablespoons 1 Tecovirimat capsule Mix entire contents of 1 Tecovirimat capsule with 2 tablespoons of liquid or soft food. 25 kg to less than 40 kg 400 mg 2 tablespoons 2 Tecovirimat capsules Mix entire contents of 2 Tecovirimat capsules with 2 tablespoons of liquid or soft food. 40 kg to less than 120 kg 600 mg 2 tablespoons 3 Tecovirimat capsules Mix entire contents of 3 Tecovirimat capsules with 2 tablespoons of liquid or soft food. 120 kg and above 600 mg 2 tablespoons 3 Tecovirimat capsules Mix entire contents of 3 Tecovirimat capsules with 2 tablespoons of liquid or soft food.
If you take more Tecovirimat SIGA than you should
Let your doctor know if you take too many Tecovirimat SIGA capsules so that your doctor can monitor you for any signs or symptoms of side effects.
If you forget to take Tecovirimat SIGA
If you miss a dose, skip that dose and continue with your next scheduled dose. Do not take a double dose to make up for a forgotten dose.
If you stop taking Tecovirimat SIGA, your symptoms may return or become worse
Do not stop taking Tecovirimat SIGA before you have completed the course, or without talking to your doctor or pharmacist first.
If you vomit after taking Tecovirimat SIGA
If you vomit within 30 minutes of taking Tecovirimat SIGA, you may take another dose right away.
If you vomit more than 30 minutes after taking Tecovirimat SIGA, do not take another dose and continue with your next scheduled dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience any of the following side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month.
Store in the original package in order to protect from light.
Store below 25 C.
Do not use this medicine if you notice that the capsule is broken or damaged in any way.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Tecovirimat SIGA contains
What Tecovirimat SIGA looks like and contents of the pack
Marketing Authorisation Holder
SIGA Technologies Netherlands B.V. Prinsenhil 29, Breda 4825 AX, The Netherlands
Manufacturer
Millmount Healthcare Limited Block-7, City North Business Campus, Stamullen Co. Meath K32 YDIreland
This leaflet was last revised in
This medicine has been authorised under exceptional circumstances . This means that for ethical reasons it has been impossible to get complete information on this medicine. The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-13b9c5485a5dae25afc0e0c660688026
Resource Composition:
Generated Narrative: Composition composition-en-13b9c5485a5dae25afc0e0c660688026
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1600/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - tecovirimat
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp13b9c5485a5dae25afc0e0c660688026
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp13b9c5485a5dae25afc0e0c660688026
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1600/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Tecovirimat SIGA 200 mg hard capsules
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en